"Thoroughly revised and reformatted, the sixth edition of Cancer Chemotherapy, Immunotherapy and Biotherapy reflects recent significant changes in cancer treatment. This newly streamlined edition contains full-color illustrations, more tables for quick reference, and new immunotherapy and molecular targeted therapy content that brings you fully up to date with the state of the art in all current cancer therapies. Key Features: Provides thorough, comprehensive coverage of the scientific and clinical aspects of immunotherapy, biotherapy, and chemotherapy. Includes significantly expanded information on immunotherapy and molecular targeted therapy, as well as the latest information on all drugs and biological agents - their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. Features a new, full-color format, a newly streamlined presentation. and more tables and figures throughout for quick access to high-yield information. Explains the rationale for use of drugs in specific schedules and combinations and offers guidelines for dose adjustment in specific situations." -- Publisher's website

Preceded by Cancer chemotherapy and biotherapy : principles and practice / editors, Bruce A. Chabner, Dan L. Longo. 5th ed. 2011.

Section I: BASIC PRINCIPLES OF CANCER TREATMENT -- 1. Clinical Strategies for Cancer Treatment: The Role of Drugs -- 2. Target Identification and Drug Discovery -- 3. Clinical Drug Development and Approval -- 4. Principles of Pharmacokinetics -- 5. Pharmacogenomics and the Role of Genomics in Cancer Therapeutics -- 6. Delivering Anticancer Drugs to Brain Tumors -- 7. Antifolates -- 8. 5-Fluoropyrimidines -- 9. Cytidine Analogues -- 10. Purine Analogs -- 11. Antimitotic Drugs -- 12. Alkylating and Methylating Agents -- 13. Platinum Analogues -- 14. Topoisomerase Inhibitors -- 15. Bleomycin, Yondelis, MMC 16. Epigenetic Agents in Oncology: HDAC Inhibitors, IDH Inhibitors, and EZH2 Inhibitors -- 17. Differentiating Agents -- 18. Asparaginase -- Section II: TARGETED AGENTS -- 19. Proteasome Inhibitors -- 20. halidomide and its Analogs in the Treatment of Hematologic Malignancies, Including Multiple Myeloma, and Solid Tumors -- 21. Targeted Therapy in Non-Small Cell Lung Cancer -- 22. MAP Kinase Pathway -- 23. CDK Inhibitors -- 24. Drugs Targeting the ABL and JAK Kinases -- 25. The PI3K/AKT/mTOR Signaling System -- 26. Inhibitors of Tumor Angiogenesis -- Section III: HORMONE ANTAGONISTS -- 27. Endocrine Therapy of Breast Cancer -- 28. Hormone Therapy for Prostate Cancer -- Section IV: IMMUNE-BASED THERAPIES 29. Monoclonal Antibodies -- 30. Cytokine Therapy for Cancer -- 31. Adoptive Cellular Therapy -- Section V: SUPPORTIVE CARE -- 32. Antiemetics -- 33. Hematopoietic Growth Factors -- 34. Cancer and Coagulopathy.

Stimson: Unlimited Users